NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella , Ph.D.
, as Chief Development Officer (CDO). "I am delighted to welcome Jim, who has been a member of our Board of Directors for the past four years, to our executive management team as Chief Development Officer," said Jennifer Good , President and CEO of Trevi Therapeutics. "Our team is planning for the pivotal development program in IPF, the advancement in refractory chronic cough, and preparing for a regulatory submission of Haduvio.
Jim will play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals. In particular, his extensive experience and execution in central nervous system (CNS) drug development together with his long-standing knowledge of Haduvio as a member of our board of directors, positions him to make an immediate impact at this important time for the Company." "I am very excited to join the team at Trevi in a direct leadership role as I see the great potential that Haduvio's central and peripheral mechanism could have on treating patients suffering from chronic cough con.